R
Robert H. Shoemaker
Researcher at National Institutes of Health
Publications - 216
Citations - 23122
Robert H. Shoemaker is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cancer & DNA damage. The author has an hindex of 55, co-authored 197 publications receiving 21697 citations. Previous affiliations of Robert H. Shoemaker include University of Bologna & Strong Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA
Jing Pan,Jing Pan,Yao Chen,Qi Zhang,Qi Zhang,Achia Khatun,Katie Palen,Gang Xin,Li Wang,Chuanjia Yang,Bryon D. Johnson,Charles R. Myers,Shizuko Sei,Robert H. Shoemaker,Ronald A. Lubet,Yian Wang,Yian Wang,Weiguo Cui,Ming You,Ming You +19 more
TL;DR: In this article, a tripeptide small molecule antagonist of VISTA CA170 was used to suppress lung tumor development in mice with the MHCII-directed KRAS peptide vaccine.
Journal ArticleDOI
A rapid in vitro method for the evaluation of potential antitumor drugs requiring metabolic activation by hepatic S9 enzymes
TL;DR: In this paper, the authors reported that incorporation of a liver subcellular fraction (S9) into a recently established cell growth inhibition assay (microculture tetrazolium assay) significantly increased the cytotoxicity of cyclophosphamide.
Journal ArticleDOI
Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers.
Altaf Mohammed,Mark Steven Miller,Ronald A. Lubet,Chen S. Suen,Shizuko Sei,Robert H. Shoemaker,M. Margaret Juliana,Fariba Moeinpour,Clinton J. Grubbs +8 more
TL;DR: It is demonstrated that significant chemopreventive efficacy could be achieved with alternative intervention regimens designed to reduce the toxicity of agents, and that starting erlotinib and/or naproxen treatments at the time microscopic tumors were present still conferred the efficacy.
Journal ArticleDOI
Role of the National Cancer Institute in acquired immunodeficiency syndrome-related drug discovery.
TL;DR: Recently, the NCI has begun efforts to bring together molecular-targeted, high-throughput screening and extramural sites with chemical libraries of interest, designed to match emerging molecular targets and high-Throughput assay technology with novel sources of chemical diversity in the extamural community.
Journal ArticleDOI
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα
Paul Klausmeyer,Thomas G. McCloud,Dominic A. Scudiero,Michael J. Currens,John H. Cardellina,Robert H. Shoemaker +5 more
TL;DR: Several of the 28 compounds assayed showed enhancement of C/EBPα induction in U937 cells, which should encourage future efforts toward obtaining and screening a larger set of both natural and synthetic analogs of this interesting group of alkaloids.